
## **Christine M Parseghian**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3375835/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge. Annals of Oncology, 2019, 30, 243-249.	1.2	170
2	Mechanisms of Innate and Acquired Resistance to Anti-EGFR Therapy: A Review of Current Knowledge with a Focus on Rechallenge Therapies. Clinical Cancer Research, 2019, 25, 6899-6908.	7.0	76
3	Circulating DNA Demonstrates Convergent Evolution and Common Resistance Mechanisms during Treatment of Colorectal Cancer. Clinical Cancer Research, 2017, 23, 4578-4591.	7.0	70
4	Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer. Clinical Cancer Research, 2017, 23, 4146-4154.	7.0	50
5	Comprehensive Clinical and Molecular Characterization of <i>KRAS</i> <sup>G12C</sup> -Mutant Colorectal Cancer. JCO Precision Oncology, 2021, 5, 613-621.	3.0	31
6	Pilot Clinical Trial of Perioperative Durvalumab and Tremelimumab in the Treatment of Resectable Colorectal Cancer Liver Metastases. Clinical Cancer Research, 2021, 27, 3039-3049.	7.0	28
7	KRAS amplification in metastatic colon cancer is associated with a history of inflammatory bowel disease and may confer resistance to anti-EGFR therapy. Modern Pathology, 2020, 33, 1832-1843.	5.5	18
8	Underreporting of Research Biopsies from Clinical Trials in Oncology. Clinical Cancer Research, 2017, 23, 6450-6457.	7.0	15
9	Assessment of Reported Trial Characteristics, Rate of Publication, and Inclusion of Mandatory Biopsies of Research Biopsies in Clinical Trials in Oncology. JAMA Oncology, 2019, 5, 402.	7.1	11
10	Overall Survival in Phase 3 Clinical Trials and the Surveillance, Epidemiology, and End Results Database in Patients With Metastatic Colorectal Cancer, 1986-2016. JAMA Network Open, 2022, 5, e2213588.	5.9	10
11	This Is Our Cells Under Pressure: Decreased DNA Damage Repair in Response to Targeted Therapies Facilitates the Emergence of Drug-Resistant Clones. Cancer Cell, 2020, 37, 5-7.	16.8	3
12	Clinical and pathologic features correlated with rare favorable survival in patients with BRAFV600E mutated colorectal cancer. Journal of Gastrointestinal Oncology, 2022, 13, 647-656.	1.4	2
13	Metastatic lung adenocarcinoma mimicking Richter transformation in a patient with chronic lymphocytic leukemia. Leukemia Research, 2020, 98, 106445.	0.8	1